US FDA extends review date for Covidien's Exalgo NDA
Tuesday, November 24, 2009 15:00 IST St Louis
Covidien, a leading global provider of healthcare products, announced that the US Food and Drug Administration (FDA) has set a new action date under the Prescription Drug User Fee Act for the review of the New Drug Application
